Pharmacological Agents Targeting the Cellular Prion Protein.

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Prion diseases involve the misfolding of cellular prion protein (PrP^C) into infectious scrapie forms (PrP^Sc) that accumulate in the brain.
• PrP^Sc is a challenging therapeutic target due to its structural heterogeneity and the existence of prion strains.
• PrP^C is increasingly recognized as a central mediator of neurotoxicity in various neurodegenerative conditions.

Purpose of the Study:

• To review compounds that target PrP^C for potential therapeutic intervention in prion diseases.
• To discuss the pharmacological properties and therapeutic potential of PrP^C-binding agents.
• To explore the broader implications of targeting PrP^C for other neurodegenerative disorders.

Main Methods:

• Literature review of studies investigating compounds that bind to PrP^C.
• Analysis of pharmacological data and anti-prion effects in experimental models.
• Discussion of the advantages of targeting PrP^C over PrP^Sc.

Main Results:

• Several classes of compounds have demonstrated anti-prion activity by interacting with PrP^C.
• Targeting PrP^C presents a promising alternative strategy due to its role as a substrate for all prion strains.
• PrP^C-targeted therapies may offer benefits beyond prion diseases, addressing shared neurotoxic pathways.

Conclusions:

• Targeting cellular prion protein (PrP^C) represents a promising therapeutic avenue for prion diseases and potentially other neurodegenerative disorders.
• Compounds binding directly to PrP^C warrant further investigation for their clinical efficacy and safety.
• Understanding PrP^C's role in neurotoxicity could unlock new treatment strategies for a range of brain diseases.